Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
GAO probe finds understaffed FDA putting some medical device recall work on the 'back burner'
(1d)
Impulse Dynamics clinches $158M for chronic heart failure implant
(2d)
2026 outlook: Biotech poised to outperform bear markets of ’21-24, analyst says
(2d)
Obesity biotech Zealand seeks partners to ‘take therapies directly to the brain’
(2d)
Arcus halts Gilead-partnered TIGIT trials as biotech reworks R&D focus
(2d)
Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share
(2d)
Chutes & Ladders—Metabolic marketing master maneuvers to CEO
(2d)
Leading the Way in Biotech Solutions Across Japan and Asia Pacific (JAPAC)
(2d)
HeartBeam swells on turning FDA rejection into ECG clearance
(3d)
Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx
(3d)
BioPharma Dive
Arcus cancels work on Gilead-partnered cancer combo after trial setback
(2d)
Praxis tees up another approval filing; Geron turns to layoffs
(2d)
AC Immune posts positive data for Parkinson’s immunotherapy
(2d)
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
(3d)
Lilly’s three-pronged drug puts obesity field ‘on notice’
(3d)
Crapo, Cassidy propose enhanced ACA subsidy alternative
(3d)
Prolynx banks $70M for longer-lasting obesity drugs
(3d)
FDA approves first drug in National Priority Voucher program
(4d)
A former Roivant spinout bets on AI-designed drugs for immune conditions
(4d)
Novartis notches another win for drug acquired in MorphoSys deal
(5d)
Endpoints News
Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more
(1d)
340B sales grew 23% last year, and court battle over pilot program intensifies
(1d)
Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources say
(1d)
A 2-speed payer transformation is underway
(2d)
CHMP calls to reject Anavex Alzheimer’s pill over impurities, side effects and weak efficacy
(2d)
#SABCS25: Celcuity further details Phase 3 win; Relay’s PI3Kα inhibitor’s consistent performance; and more
(2d)
Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancers
(2d)
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor
(2d)
GSK spins out corporate VC fund focused on bioelectronic tech
(2d)
Tenaya targets $60M offering after heart disease pipeline updates
(2d)
BioSpace
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure
(2d)
FDA Plans Black Box Warning for COVID-19 Vaccines: Report
(2d)
Amgen Scores Uplizna Expansion Into Generalized Myasthenia Gravis
(2d)
GSK’s Blujepa Opens First New Class of Gonorrhea Antibiotic in More Than 30 Years
(2d)
CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths
(2d)
Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot
(2d)
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
(3d)
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
(3d)
FDA Is Built on Predictability and Expertise, Not Norm-Breaking
(3d)
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
(3d)
STAT News
STAT readers respond to essays on miracles, vaccines, and more
(1d)
Everything is changing in dementia diagnosis and treatment
(1d)
Trump order blocking state AI laws could slow health AI adoption, leave patients vulnerable
(1d)
FDA approves first new kind of drug to target gonorrhea in decades
(1d)
As superbug fears grow, sales of antibiotics used in food-producing livestock rose dramatically last year
(2d)
Medicare routes $16 billion to insurers to offset high drug costs
(2d)
Up and down the ladder: The latest comings and goings
(2d)
Europe proposes shortening drug exclusivity period
(2d)
We’re reading about FDA staff fears, a Lilly weight loss drug and much more
(2d)
Pharmacy staffing levels at a ‘breaking point’
(2d)
BioPharma Trend
Unified Discovery: How ASCEND's Conversational AI Bridges Internal and Public Data for Accelerated Oncology Insights
(4d)
Insilico Medicine Reports AI-Designed PROTAC That Degrades and Inhibits PKMYT1
(4d)
Why European Life Science’s Momentum May Finally Become Unstoppable
(6d)
Ginkgo Bioworks Launches Open-Source Pharmacology Framework for AI Drug Discovery
(3w)
Antheia and TAPI Announce Strategic Partnership to Scale Biosynthetic Pharmaceutical Manufacturing
(3w)
Terray Launches Experiment-Driven Machine Learning Platform for Small-Molecule Discovery
(4w)
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(1mo)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(1mo)
Companies Making Automated Drug Discovery a Reality
(1mo)
Five Companies Leading the Way in 3D Bioprinting
(1mo)
Drug Channels
Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (rerun)
(2d)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices (rerun)
(3d)
Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)
(4d)
Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies (rerun)
(5d)
How Large PBMs Make Money Today: A 2025 Drug Channels Update (rerun)
(6d)
Closing the Specialty Access Gap: How GoodRx Turns Intent Into Therapy Starts
(1w)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs
(2w)
The Hidden Burdens of Cancer Care: When Insurers Override Doctors
(3w)
Drug Channels News Roundup, November 2025: PBM Revolution, Cuban’s Stelara Challenge, Express Scripts’ Price Games, U.S. Drug Spending Reality, and the AFP Reckoning
(4w)
The $700 Copay That Changed Everything
(1mo)
European Biotechnology Magazine
Berlin: Why Start-ups Choose Bayer Co.Lab
(2d)
Zealand pays Chinese OTR US$30m upfront to expand obesity pipeline
(2d)
Lilly‘s retatrutide delivers record weight loss
(2d)
Pfizer presents data for Tukysa in HER2-positive breast cancer
(2d)
Roche presents details on breast cancer pill giredestrant
(2d)
Disco Pharmaceuticals GmbH expands seed financing
(3d)
Tetraneuron secures funding for Alzheimer’s gene therapy trial
(3d)
Selecting a CDMO for Custom Activated PEGs
(4d)
Cellular Origins secures major CGT funding breakthrough
(5d)
SLAS announces finalists for the 2026 Ignite Award
(5d)
Drug Hunter
A Compendium of Pharmaceutically Used Salts to Help Flavor Your Drug Formulation
(2d)
gedatolisib
(3d)
JNJ-8003
(4d)
bitopertin (DISC-1459)
(4d)
sevabertinib (BAY 2927088)
(6d)
imlunestrant
(1w)
STAT6: A Challenging Target Gains Traction Utilizing Degraders for Th2-Driven Disease
(1w)
VVD-214/RO7589831
(1w)
Guide to FDA Designations
(1w)
2025 Medicinal Chemistry Reviews at a Glance
(2w)
Labiotech.EU
Fifteen gift ideas for a biotech enthusiast this holiday season
(2d)
Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach
(2d)
Promising cure for COPD: Is a breakthrough treatment within reach?
(4d)
When AI isn’t enough: How physics is shaping the next wave of drug discovery
(5d)
How world-class infrastructure will reinforce Ghent’s position as Europe’s biopharma hub
(5d)
Top biotech deals in November 2025
(6d)
The biggest biotech funding rounds in November 2025
(1w)
Cracking Cancer’s Code: Transforming Research with Novel Cancer Models
(1w)
Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025
(2w)
Greener pastures for biopharma? Biotechs in Ireland causing a stir
(2w)
Bio IT World
Modeling and Shared Compute Reveals Pathways of Synthetic Drug
(2d)
Rethinking Precision Oncology in the Age of Functional Data
(3d)
Oxford Nanopore's Newly Named CEO Brings Diagnostics Expertise
(6d)
National University of Singapore Launches First Global Medical AI Foundation Model
(1w)
How Next-Gen Biotechnology Is Transforming Genetic Risk Prediction
(2w)
Psychedelics and Patient Selection Tools Propelling Precision Psychiatry
(2w)
Follow the Money: Enveloped Delivery Vehicle Technology, Oral Medication for Inflammatory, Neurological Diseases, More
(3w)
Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina
(3w)
Ginkgo Datapoints Launches Virtual Cell Pharmacology Initiative
(3w)
The Women’s Health Gap: 5 Cautionary Tales of Clinical Blunders
(4w)
GEN News
CRISPR Streamlines Goldenberry Growth to Enable Large-Scale Farming
(1d)
Concordia University Expands Sustainable Biomanufacturing Capacity with $5M Investment
(2d)
Ebola and Marburg-Induced Gut Damage Modeled Using Organoids
(2d)
Next-Gen CAR T Cells Destroy Cancer Cells with Fewer Toxic Effects in Mice
(3d)
Mutations in Mitochondrial Genes Ameliorate Pathology in Friedreich’s Ataxia Model
(3d)
Immune Switch Critical for Modulating Autoimmunity Identified in Mice
(3d)
Monkeypox Vaccine Breakthrough: AI Reveals New Target
(3d)
Lung Microbial Communities May Influence Pneumonia Recovery
(3d)
Scientists Calibrate Raman Spectroscopy without Running a Bioreactor Process
(4d)
Novel AI Drug Toxicity Models to Improve Drug Safety to Be Developed by an Industrial-Academic Group
(4d)
Cure Today
Stage 3 Prostate Cancer: A Guide to Diagnosis, Treatment, and Next Steps
(1h)
Bladder Adenocarcinoma: An Overview for the Newly Diagnosed
(21h)
Rising Lung Cancer Rates Targets Asian Women Nonsmokers in California
(1d)
Fertility Decisions Influenced by Age and Parental Status in Premenopausal Breast Cancer
(1d)
Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer
(1d)
FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer
(1d)
HRT Use Does Not Raise Breast Cancer Risk in BRCA Carriers
(2d)
Electronic Intervention Improves Quality of Life in Younger Breast Cancer Survivors
(2d)
Acupuncture Improves Cognitive Function in Breast Cancer Survivors
(2d)
Suleika Jaouad, Reporting From the Front Lines of Leukemia
(2d)
Contract Pharma
An Inside Look at Integrated Process Solutions at Glatt’s NJ Site
(2d)
Zealand Pharma, OTR Therapeutics Sign Deal to Develop Metabolic Disease Treatments
(2d)
Lilly to Invest $6B in New API Manufacturing Facility in Alabama
(2d)
Integrated Excellence: A Unified Approach To Development, Manufacturing, Testing, And Storage
(2d)
Leadership Transition at Vetter: Thomas Otto Retires
(3d)
Developer of ‘Physical AI Scientists’ Raises $52M
(3d)
Charles River Announces Latest Cohort of Its Cell & Gene Therapy Incubator Program
(3d)
Eliminating Complexity for Pharma Teams
(4d)
Cytiva, Fidabio Partner to Expand Analytical Capabilities for Protein Research
(4d)
The Wellcome Sanger Institute Selects Sapio Informatics as Its Central LIMS
(4d)
Pharma Times
Miranda Dini launches GOLD amid industry shifts
(3d)
Genfit reports promising phase 1b data in cholangiocarcinoma
(3d)
GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis
(3d)
Immunotherapy combination shows unprecedented results in multiple myeloma
(4d)
Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia
(4d)
Five-year study confirms durable efficacy of etranacogene dezaparvovec
(5d)
Enterprise Therapeutics publishes results of phase 1 study of ETD001
(5d)
Rybrevant accepted in Scotland for lung cancer treatment
(6d)
Early use of CARVYKTI shows lasting remissions in multiple myeloma
(6d)
Bayer begins phase 2 trial of new Alport syndrome therapy
(1w)
Medcity News
Trade Restrictions on Medical Equipment? Proceed With Caution
(1h)
Making Exercise a Standard in Cancer Survivorship Care
(1h)
Health Experts Warn of ‘Devastating’ Impact After Senate Rejects ACA Tax Credit Extension
(1d)
4 Things to Know About Texas’ Lawsuit Against Epic
(1d)
Top Telemedicine Services for Hospitals: Leading Solutions Compared
(2d)
Cut Through The Hype: 3 Things To Know Before Adopting Agentic AI
(2d)
Omaha ABA Therapy: Comparing the Top Providers
(2d)
Reducing EMS Documentation Time Without Sacrificing Accuracy
(2d)
Vanderbilt CEO: Health Systems Can Fix Prior Auth Without Waiting for Payers
(2d)
MedCity Pivot Podcast: A Flexible Approach to Pharmacy Benefits Management
(2d)
Chemical & Engineering News
Daily scenes from Pacifichem 2025
(1d)
Dec. 12 Policy Watch: FDA proposes first new sunscreen molecule since 1996
(1d)
Obituary: Margaret A. Matthews
(2d)
Crossword: Searching the literature
(2d)
Baton Rouge Local Section names 2025 Coates award winner
(2d)
Practice career flexibility
(2d)
Chemistry in Pictures: Festive glow
(2d)
ProLynx raises $70 million to develop its long-lasting weight-loss drug pipeline
(3d)
Start-ups advance US magnesium plans
(3d)
Comment: Getting involved in American Chemical Society initiatives
(3d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to December 12
(4h)
PsiThera
(11h)
Five novel medicines backed for approval by EMA/CHMP
(1d)
FDA approves two oral therapies to treat gonorrhea
(1d)
AstraZeneca backs Syneron Bio in near-$100m financing
(2d)
Cycle Pharma to acquire Applied Therapeutics
(2d)
Sidera Bio lands $109 million series A in rare Danish megaround
(2d)
INTERPHEX
(2d)
BioCryst’s Orladeyo wins expanded FDA approval
(2d)
Rezolute decimated on Phase III miss for ersodetug
(2d)
Targeted Oncology
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
(13m)
The Targeted Pulse: Blood and Breast Cancer News
(4h)
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
(1d)
Phase 3 Trial of Olverembatinib Cleared By FDA, EMA in Ph+ALL
(1d)
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
(1d)
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
(1d)
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i
(1d)
Dual BCMA/CD19 CAR T-Cell Therapy Shows Deep and Durable Responses in MM
(1d)
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
(1d)
Remote Monitoring Reduces Hospitalizations for Patients With Blood Cancers
(1d)
MedWatch
Another change to Leo Pharma's management: Strategy manager leaves for Swedish company
(2d)
US FDA likely to speed up review of Eli Lilly's weight loss pill
(2d)
Indian diabetes patients gain access to Novo Nordisk drug
(2d)
GN's VP of Group Communication steps down
(2d)
Bavarian thinks investors will back new acquisitions: The test will come “when we actually ask for the money”
(2d)
Genmab completes acquisition of Dutch biotech company Merus
(2d)
Zealand Pharma to quintuple research costs as part of new strategy
(2d)
Creditor files for bankruptcy in distressed hearing aid company
(3d)
Industry passes judgment on new drug regulation: Better than feared, but a blow to Europe's competitiveness
(3d)
Former Coloplast CEO becomes chair and co-owner of Danish health tech-startup
(3d)
In The Pipeline
Old-Time Bacterial Plasmids Vs. Modern Days
(2d)
Mirror-Imaging Your Way Through
(3d)
A Sandmeyer Replacement
(5d)
What's Happening At the Water Surface Anyway?
(1w)
Fixing A Reaction
(1w)
Another GLP-1 Alzheimer's Trial
(1w)
Complete Regulatory Chaos
(2w)
Cheap Computation of Small Peptide Binders
(2w)
Alzheimer's Clinical Trial Results, Sadly Running True to Form
(3w)
Alcohol And Fructose, Tangled (and Untangled?)
(3w)
Pharmaphorum
CHMP decision levels the playing field for GSK's RSV jab
(2d)
UK teams up with Singapore on healthtech regulation
(2d)
SanegeneBio raises $110m for RNAi, plus other financings
(2d)
FDA clears first at-home device for depression
(3d)
Agreement reached on EU's new pharma legislation
(3d)
Lilly's obesity triple pulls off 29% weight loss in trial
(3d)
AC Immune says Parkinson's drug slows progression
(3d)
Pfizer makes first-line case for Tukysa in breast cancer
(3d)
Roche delivers its data reveal for adjuvant giredestrant
(3d)
Pfizer's $2bn+ obesity bet, and other weight-loss news
(3d)
Drug Discovery Weekly
This week in Drug Discovery (8 – 12 December)
(2d)
ARC, Mount Sinai and NVIDIA team up to decode the human genome
(2d)
Study supports hippocampal volume as marker in Alzheimer’s
(2d)
Pfizer boosts weight loss pipeline with GLP-1 drug
(2d)
Relation and Novartis to advance atopic disease therapeutics
(3d)
MaaT013 shows strong survival rate in aGvHD patients
(3d)
UK payment rate for new medicines drops to 14.5% in 2026
(4d)
Pirtobrutinib more effective than ibrutinib, study finds
(4d)
Drug shows ‘unprecedented’ response in chronic myeloid leukaemia
(4d)
Gum cells show potential as cure for knee arthritis
(4d)
HIT Consultant
Deloitte 2026 Outlook: Why Traditional Health Strategies Will Fail in the Face of Regulatory Uncertainty
(2d)
The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags
(2d)
From Confusion to Collections: How Unclear Billing Fuels the Medical Debt Crisis
(2d)
Beyond the Margin Squeeze: How Specialty Providers Use RCM Automation to Combat Rising Costs
(2d)
FDA Clears Ceribell’s AI-Powered EEG as First Device for Continuous Delirium Monitoring
(2d)
Fighting Physician Burnout: OhioHealth Deploys Abridge AI Across 200+ Care Sites
(2d)
AdventHealth and UCF Transform Lake Nona into a Robotic Surgery and Simulation Epicenter
(2d)
Joy Parenting Club Acquires Heba Care to Scale the First Comprehensive, AI-Powered Parenting Platform
(3d)
KLAS 2025 Report: Chartis and Impact Advisors Lead as Hospitals Seek IT Planning Expertise
(3d)
Valinor Raises $13M to Predict Clinical Trial Outcomes Using Multi-Omic AI
(3d)
Insights: Pink Sheet
Expectations Mount Prasad Again Will Overrule US FDA Vaccine Reviewers On COVID-19 Shot Safety
(1d)
BsUFA IV: Approval Criteria Shift May Mean US FDA User Fee Changes
(1d)
Can US FDA Balance Inspection Generalists And ‘Simple Reform’ With Need For Expertise?
(1d)
UK & Singapore Launch Joint AI-Supported Regulatory Collaboration
(2d)
How To Successfully Navigate The UK’s New Pathway To Get Medicines To Patients More Quickly
(2d)
CAR-Ts Win Big In New China Drug Coverage Lists
(2d)
US Government Backs Hikma In Vascepa Skinny Label Case, Suggests SCOTUS Review
(2d)
Study Says 340B Rebate Model Will Not Disrupt Provider Cash Flows, Despite Concerns
(2d)
PDUFA VIII: Industry Questions ‘America First’ Fee Incentives
(2d)
‘More Work Needed’ To Restore UK Pharma Competitiveness Despite Rebate Rate Cut
(3d)
BioXconomy
Gen Z and Millennials favor Excel
(1d)
Medline targets $5.37bn in landmark IPO
(2d)
Ventures Accelerated: A platform for precision and connection in life sciences
(2d)
A year of firsts: The BioXconomy Modalities team’s favorite innovations of 2025
(2d)
Novartis pens deal with UK biotech worth up to $1.7bn
(3d)
Paradigm Health acquires Flatiron clinical research unit, raises $78m to expand trial access
(3d)
USPS changes spark concerns over mail-order pharmacy access
(4d)
Monoclonal antibody shows promise as a treatment for Alzheimer’s disease
(4d)
British Business Bank invests $100m in fund to boost UK life sciences
(4d)
Latest appointments to key compliance and governance positions
(4d)
BioCentury
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression
(1d)
Makary’s embrace of ideology, conspiracies puts FDA at risk: A Perspective
(1d)
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics
(1d)
BeOne strengthens its BTK position at ASH
(1d)
After huge day, more follow-ons lift week’s total to nearly $4.5B: Public Equity Report
(1d)
Lilly’s triple agonist contender for best-in-class weight loss
(2d)
BioCentury’s FDA survey reflects an industry in distress
(2d)
Front Row with BioCentury: Inside the turbulent ride of cell and gene therapy
(2d)
Science Spotlight: Chinese researchers advance PROTAC design
(2d)
AC Immune’s Parkinson’s vaccine advances on promising biomarker profile
(2d)
SCRIP
Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet
(1d)
GSK Sees Community Niche For Blenrep, But Bispecifics Are Making Inroads
(1d)
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination
(1d)
AC Immune Perks Up On Positive Parkinson’s Data
(2d)
Top 10 Drugs Q3 2025: Obesity Gold Rush Helps Add $10bn To Revenues
(2d)
Biologics-In-A-Pill Firm PsiThera Launched With Series A $47.5m
(2d)
Executives On The Move: Kriya Therapeutics Gets A New CMO From Pfizer
(2d)
ASH: Early Results Ready Lupeng’s Rocbrutinib For Potential Head-To-Head With Jaypirca
(2d)
Quotable: Words Of Wisdom From Our Recent APAC Coverage
(2d)
Scrip Awards 2025 Spotlight Industry Triumphs
(2d)